The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: a preliminary investigation11No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated.

2004 ◽  
Vol 85 (6) ◽  
pp. 902-909 ◽  
Author(s):  
Catherine A Johnson ◽  
Jane H Burridge ◽  
Paul W Strike ◽  
Duncan E Wood ◽  
Ian D Swain
Toxins ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 303
Author(s):  
Alessandro Picelli ◽  
Mirko Filippetti ◽  
Giorgio Sandrini ◽  
Cristina Tassorelli ◽  
Roberto De Icco ◽  
...  

Botulinum toxin type A (BoNT-A) represents a first-line treatment for spasticity, a common disabling consequence of many neurological diseases. Electrical stimulation of motor nerve endings has been reported to boost the effect of BoNT-A. To date, a wide range of stimulation protocols has been proposed in the literature. We conducted a systematic review of current literature on the protocols of electrical stimulation to boost the effect of BoNT-A injection in patients with spasticity. A systematic search using the MeSH terms “electric stimulation”, “muscle spasticity” and “botulinum toxins” and strings “electric stimulation [mh] OR electrical stimulation AND muscle spasticity [mh] OR spasticity AND botulinum toxins [mh] OR botulinum toxin type A” was conducted on PubMed, Scopus, PEDro and Cochrane library electronic databases. Full-text articles written in English and published from database inception to March 2021 were included. Data on patient characteristics, electrical stimulation protocols and outcome measures were collected. This systematic review provides a complete overview of current literature on the role of electrical stimulation to boost the effect of BoNT-A injection for spasticity, together with a critical discussion on its rationale based on the neurobiology of BoNT-A uptake.


2011 ◽  
Vol 24 (2) ◽  
pp. 126-132 ◽  
Author(s):  
Jee-Woong Choi ◽  
Choon-Shik Youn ◽  
Hi-Tae An ◽  
Jong-Yeop Yoo ◽  
Jung-Im Na ◽  
...  

2020 ◽  
pp. 54-60
Author(s):  
O. A. Egorova

The article presents current data on etiology and pathogenesis rosacea, listed endogenous and exogenous provoking factors. The pathogenetic justification given of the use of botulinum toxin type A in erythematosus-teleangiectatic subtype rosacea. A study involving 32 patients with ETP was carried out, during which a combination treatment was used – a course of microcurrent therapy followed by botulinum therapy by mesotechnics (in two different breedings). According to the results of the study, a pronounced clinical effect was established in patients. The results were evaluated using an analog VAS scale as well as DIQL. We came to conclusions about the effectiveness of combined use of microcurrent therapy and botulinum therapy in erythematosus-teleangiectatic subtype rosacea and the feasibility of further study of this issue.


Sign in / Sign up

Export Citation Format

Share Document